Compare Novo Nordisk A/S (NVO) vs Rent the Runway Inc (RENT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Rent the Runway Inc — how do they compare? Novo Nordisk A/S trades at $38.49 (market cap $165.31B), while Rent the Runway Inc trades at $1.74 (market cap $61.75M). The key difference: Novo Nordisk A/S is far larger — about 2677.1× Rent the Runway Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Rent the Runway Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Rent the Runway Inc for 56 Days on average.
| NVO | RENT | |
|---|---|---|
Market Cap | $165.31B | $61.75M |
Volume | 11,432,838 | 193,323 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $9.39 |
52-Week Low | $35.29 | $1.55 |
Typical Hold Time | 116 Days | 56 Days |
Enterprise Value | $179.56B | $228.75M |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
RENT trades at $1.765, up 5.06% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported revenue of $306.20M in 2025 with improving net loss margins, yet negative shareholder equity and high debt-to-asset ratios persist. Recent news includes a CEO appointment and multiple law firm investigations into investor claims, creating a complex sentiment backdrop.
The outlook remains challenged by financial instability and legal scrutiny, though analyst consensus leans buy with no sell ratings. Key risks include high leverage and ongoing losses, while potential upside hinges on execution of growth initiatives and margin improvement. Investors face significant volatility amid restructuring efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
